Respiratory

Mesothelioma: occupational exposure and management

Clinical Overview and When to Suspect Mesothelioma

— Latency is 20–50 years between first exposure and diagnosis.

— All fiber types are carcinogenic, but amphiboles (crocidolite, amosite) are more potent than chrysotile.

— Even brief or low-dose exposure can cause disease — no safe threshold.

— Unilateral pleural effusion that recurs after thoracentesis

— Persistent chest wall pain, dyspnea, weight loss

— Occupational history positive for asbestos

— Imaging showing pleural thickening, nodularity, or pleural plaques (markers of exposure, not malignancy themselves)

Board pearl: Pleural plaques on CT signal asbestos exposure but are benign — they do not become mesothelioma. However, their presence in a symptomatic patient with effusion dramatically raises pretest probability and mandates tissue diagnosis, not just cytology.

Malignant mesothelioma is an aggressive neoplasm of mesothelial surfaces — pleura (~80%), peritoneum (~20%), and rarely pericardium or tunica vaginalis testis.

Asbestos exposure is the dominant risk factor, accounting for ~80% of cases.

High-risk occupations: shipyard workers, pipefitters, boilermakers, insulators, brake/clutch mechanics, construction/demolition workers, plumbers, electricians, Navy veterans, railroad workers, and oil refinery employees.

Non-occupational exposures: household contacts of asbestos workers (fibers on clothing), residents near asbestos mines, and erionite exposure (Turkey, North Dakota road gravel).

Other risk factors: prior chest radiation (especially for Hodgkin lymphoma, breast cancer), SV40 virus (controversial), and germline BAP1 mutation (BAP1 tumor predisposition syndrome — also predisposes to uveal melanoma, renal cell carcinoma).

Smoking is NOT independently causative, but synergistically increases lung cancer risk in asbestos-exposed patients (multiplicative for lung cancer, not mesothelioma).

Suspect mesothelioma in a patient aged 60–80 with:

Presentation Patterns and Key History

— Insidious dyspnea (60–90%) from pleural effusion or restrictive encasement

— Non-pleuritic, dull, persistent chest wall pain (60%) — often the most distinguishing symptom vs simple effusion

— Dry cough, fatigue, unintentional weight loss, night sweats

— Hoarseness (recurrent laryngeal nerve invasion), dysphagia, or SVC syndrome with advanced disease

— Abdominal distension, ascites, vague pain, early satiety, weight loss

— Often misdiagnosed as ovarian cancer or carcinomatosis of unknown primary

— Detailed occupational history going back 50 years — every job, duration, role, materials handled

— Second-hand exposure: spouse/parent who worked with asbestos and brought fibers home on clothing

— Military service (especially Navy 1940s–1970s)

— Home renovations of pre-1980 buildings (insulation, floor tiles, popcorn ceilings)

— Prior thoracic radiation

— Family history of mesothelioma, uveal melanoma, or RCC → consider BAP1 germline testing

— Smoking history (affects prognosis, lung cancer risk, surgical candidacy)

Key distinction: Chest pain in mesothelioma is somatic chest wall pain — dull, constant, worsens with disease progression, often poorly relieved by NSAIDs. Contrast with pleuritic pain of infection or PE (sharp, respirophasic) or anginal pain (exertional, substernal).

Step 3 management: When taking the occupational history, ask specifically: "Did you ever work with insulation, brake pads, shipbuilding, or in a pre-1980 industrial facility?" Patients often do not recognize asbestos exposure without prompting. Document exposure dates precisely — this is essential for workers' compensation and asbestos trust fund claims later.

Pleural mesothelioma — most common presentation:

Peritoneal mesothelioma (~20%):

Pericardial (<1%): pericardial effusion, tamponade, constrictive physiology.

Tunica vaginalis (<1%): painless scrotal mass or hydrocele.

Critical history elements (must document):

Physical Exam Findings (and Hemodynamic Assessment)

— Decreased chest wall expansion on affected side

— Dullness to percussion over effusion; stony dull if massive

— Diminished or absent breath sounds, decreased tactile fremitus

— Egophony above the effusion level

— Tracheal deviation — toward the affected side suggests trapped lung or volume loss from tumor encasement (key mesothelioma sign), away suggests massive effusion under tension

— Palpable chest wall mass or tenderness at prior thoracentesis/biopsy sites (tract seeding)

— Clubbing (~10%) — less common than in lung cancer

— Distension, shifting dullness, fluid wave, palpable omental cake, umbilical (Sister Mary Joseph) nodule rare

— Hypotension + JVD + muffled sounds (Beck's triad) → pericardial tamponade

— Facial plethora, dilated neck veins, arm swelling → SVC syndrome

— Hypoxia disproportionate to effusion size → trapped lung or lymphangitic spread

Board pearl: Tracheal deviation toward a large unilateral opacity is a classic mesothelioma clue — the rigid pleural rind contracts the hemithorax rather than pushing the mediastinum away, distinguishing it from a simple massive effusion.

Step 3 management: Always inspect and palpate prior procedure sites (thoracentesis, chest tube, biopsy). Subcutaneous nodules at these sites represent tract metastases — a pathognomonic mesothelioma behavior that informs the rationale for prophylactic radiotherapy to instrumented sites in some protocols.

General appearance: cachexia, pallor, fatigue in advanced disease; may appear deceptively well early.

Vital signs: usually normotensive; tachypnea and hypoxia with large effusions; fever uncommon (raises suspicion for empyema or paramalignant infection).

Thoracic exam — pleural disease:

Abdominal exam — peritoneal disease:

Lymphadenopathy: supraclavicular or axillary nodes suggest advanced/metastatic disease.

Cardiac: muffled heart sounds, pulsus paradoxus, elevated JVP if pericardial involvement → assess for tamponade physiology.

Hemodynamic red flags:

Diagnostic Workup — Initial Labs and Imaging

— CBC: anemia of chronic disease, thrombocytosis (poor prognostic marker)

— CMP: assess renal/hepatic function before chemotherapy/contrast

— LDH: elevated in advanced disease, prognostic

— Coagulation studies before procedures

— Serum biomarkers: mesothelin (SMRP) and osteopontin — elevated in epithelioid mesothelioma but not sensitive/specific enough for diagnosis or screening; may be used for monitoring response in known cases.

— Unilateral pleural effusion (most common finding)

— Pleural thickening, nodularity, "lobulated" pleural contour

— Pleural plaques (often calcified, bilateral, diaphragmatic) — marker of asbestos exposure

— Ipsilateral volume loss with mediastinal shift toward the lesion

— Interstitial fibrosis (asbestosis) may coexist

— Circumferential, nodular pleural thickening >1 cm

— Mediastinal pleural involvement (highly suggestive)

— Pleural rind encasing the lung ("frozen hemithorax")

— Interlobar fissural thickening

— Chest wall invasion, rib destruction, diaphragmatic invasion

— Mediastinal lymphadenopathy

— Contralateral pleural plaques supporting asbestos etiology

— Exudative by Light's criteria (high LDH, high protein)

— Often bloody/serosanguinous

— Low glucose, low pH in advanced disease

— Cytology has poor sensitivity (~30%) for mesothelioma — a negative cytology does NOT rule out disease

Key distinction: Pleural plaques (smooth, often calcified, parallel to chest wall, bilateral) = benign asbestos marker. Pleural thickening that is nodular, circumferential, >1 cm, involves mediastinal pleura, or encases the lung = malignant until proven otherwise.

Step 3 management: Do not repeatedly tap a recurrent unilateral effusion in an asbestos-exposed patient hoping for cytologic diagnosis — after one negative cytology, escalate directly to tissue biopsy via image-guided core or VATS.

Initial labs (limited diagnostic value, but support staging and fitness):

Chest X-ray (first imaging study):

CT chest with IV contrast — workhorse imaging:

Thoracentesis (often first invasive step):

Diagnostic Workup — Confirmatory and Staging Studies

— VATS (video-assisted thoracoscopic surgery) pleural biopsy is the gold standard — provides large samples, allows direct visualization, enables talc pleurodesis at the same setting.

— Image-guided core needle biopsy (CT or US) — alternative when VATS not feasible.

— Avoid blind closed pleural biopsy (Abrams/Cope) — low yield for mesothelioma.

— Epithelioid (~60%) — best prognosis, most chemo/surgery responsive

— Sarcomatoid (~20%) — worst prognosis, often unresectable

— Biphasic/mixed (~20%) — intermediate

— Desmoplastic variant — particularly aggressive

— Positive in mesothelioma: calretinin, WT-1, cytokeratin 5/6, D2-40 (podoplanin), mesothelin

— Positive in adenocarcinoma: TTF-1, napsin A, CEA, MOC-31, BerEP4, claudin-4

— Loss of BAP1 by IHC and CDKN2A (p16) deletion by FISH help distinguish malignant mesothelioma from reactive mesothelial hyperplasia

— PET-CT: detects nodal and distant metastases, evaluates resectability

— MRI chest: best for chest wall, diaphragm, mediastinal invasion

— EBUS or mediastinoscopy: pathologic N2/N3 nodal staging if surgery considered

— Laparoscopy: rule out transdiaphragmatic peritoneal spread before EPP

— Stage I–II: potentially resectable

— Stage III–IV: locally advanced or metastatic

Board pearl: BAP1 loss + CDKN2A homozygous deletion on a pleural biopsy essentially confirms malignant mesothelioma and excludes reactive mesothelial proliferation — a frequent diagnostic pitfall.

Step 3 management: Refer every newly diagnosed mesothelioma to a multidisciplinary thoracic oncology center — outcomes are markedly better in high-volume centers offering trimodality therapy and clinical trials.

Tissue biopsy is mandatory for diagnosis — cytology alone is insufficient.

Histologic subtypes (prognostically critical):

Immunohistochemistry distinguishes mesothelioma from adenocarcinoma:

Staging studies (after diagnosis confirmed):

TNM staging (IMIG/AJCC 8th ed) drives treatment:

Risk Stratification and First-Line Management Logic

— Histologic subtype (epithelioid = candidate for aggressive therapy)

— Stage (I–II resectable vs III–IV palliative)

— Performance status (ECOG 0–1 required for trimodality)

— Pulmonary reserve (predicted post-op FEV1, DLCO)

— Comorbidities, age, patient preference

— Curative-intent multimodality — early-stage epithelioid, fit patient

— Systemic therapy + palliative local control — most patients

— Best supportive/palliative care — sarcomatoid, poor PS, advanced disease

— Sarcomatoid histology

— Non-epithelioid subtype

— Male sex, age >75

— Poor performance status

— Weight loss >10%

— Thrombocytosis, leukocytosis, high LDH, anemia

— Chest pain at presentation

— Nodal involvement

— Median survival untreated: 6–9 months

— With chemotherapy: 12–18 months

— Selected trimodality candidates: 20–30+ months

— 5-year survival: <10% overall

— Pleurectomy/decortication (P/D) — lung-sparing, lower morbidity

— Extrapleural pneumonectomy (EPP) — removes lung, pleura, pericardium, hemidiaphragm; higher morbidity, used less often now

— Current trend favors P/D + chemo ± radiation over EPP

Step 3 management: For a 70-year-old with epithelioid pleural mesothelioma, ECOG 1, and stage II disease, the right answer is referral to a specialized center for multimodality therapy (chemo + surgery ± radiation) — NOT immediate palliative care.

Board pearl: Sarcomatoid histology is essentially a contraindication to aggressive surgery — these patients receive systemic therapy ± palliation.

Treatment intent is determined by:

Three management tiers:

Prognostic factors (poor):

EORTC and CALGB prognostic scoring systems stratify patients.

Overall prognosis remains grim:

Surgical options (curative intent, only in selected centers):

Pharmacotherapy — First-Line Systemic Regimens

— Cisplatin + pemetrexed every 21 days × 4–6 cycles

— Add bevacizumab (anti-VEGF) in eligible patients — improved OS in MAPS trial (cisplatin + pemetrexed + bevacizumab vs without)

— Carboplatin can substitute for cisplatin in elderly/renal impairment with comparable efficacy

— Antifolate (inhibits thymidylate synthase, DHFR, GARFT)

— Mandatory supplementation: folic acid 350–1000 mcg PO daily (start 1 week before) and vitamin B12 1000 mcg IM every 9 weeks — reduces hematologic and GI toxicity dramatically

— Dexamethasone premedication to prevent rash

— Toxicities: myelosuppression, mucositis, fatigue, rash, nephrotoxicity

— Renal dosing: avoid if CrCl <45 mL/min

— Nephrotoxicity (mandatory IV hydration pre/post), ototoxicity, neuropathy, severe nausea (use 5-HT3 + NK1 + dexamethasone antiemetics), electrolyte wasting (Mg, K)

— Nivolumab + ipilimumab (PD-1 + CTLA-4 blockade) approved as first-line for unresectable mesothelioma

— Particularly beneficial in non-epithelioid (sarcomatoid/biphasic) subtypes where chemo response is poor

— Toxicities: immune-related adverse events (colitis, pneumonitis, hepatitis, endocrinopathies — thyroid, hypophysitis, adrenal insufficiency)

— Single-agent immunotherapy (nivolumab or pembrolizumab)

— Vinorelbine, gemcitabine

— Clinical trial enrollment strongly encouraged

Board pearl: Always pre-medicate pemetrexed patients with folic acid and B12. Forgetting this is high-yield — leads to severe myelosuppression and is a classic exam stem.

Step 3 management: For non-epithelioid (sarcomatoid/biphasic) mesothelioma, nivolumab + ipilimumab is preferred over chemotherapy as first-line — this is a recent guideline shift worth knowing.

First-line standard of care (historical and still widely used):

Pemetrexed:

Cisplatin:

Immunotherapy — first-line option (CheckMate 743):

Second-line and beyond:

Procedures, Surgery, and Local Therapies

— Pleurectomy/decortication (P/D): stripping of parietal and visceral pleura; preserves lung; lower mortality (~2%); now generally preferred

— Extended P/D: adds resection of diaphragm and/or pericardium

— Extrapleural pneumonectomy (EPP): en bloc removal of lung, parietal/visceral pleura, ipsilateral diaphragm, pericardium — high morbidity (~25%) and mortality (~5–7%); falling out of favor (MARS trial showed no benefit)

— Neoadjuvant chemo → surgery → adjuvant hemithoracic radiation

— Or surgery → adjuvant chemo ± RT

— Hemithoracic IMRT post-surgery to reduce local recurrence

— Palliative RT for chest wall pain, painful chest wall masses, SVC syndrome

— Prophylactic RT to procedure tracts — historically used to prevent tract seeding (now controversial after SMART/PIT trials showed limited benefit)

— Talc pleurodesis via VATS or chest tube — first-line for symptomatic recurrent effusion if lung re-expands

— Indwelling pleural catheter (IPC) (PleurX) — preferred when trapped lung is present or recurrence anticipated; allows outpatient drainage

— Combination IPC + talc (AMPLE-2) increasingly used

— Cytoreductive surgery + HIPEC (heated intraperitoneal chemo with cisplatin) at specialized centers — dramatically improved survival (median 50+ months) in selected patients

CCS pearl: For a patient admitted with massive symptomatic malignant pleural effusion and trapped lung, place an indwelling pleural catheter, order outpatient home drainage teaching, schedule oncology follow-up within 1 week, and arrange palliative care consult — this is the high-value, board-aligned sequence.

Board pearl: HIPEC + cytoreduction transforms peritoneal mesothelioma prognosis — refer early, before extensive carcinomatosis develops.

Surgical resection — only in carefully selected, fit patients with epithelioid disease at high-volume centers:

Multimodality (trimodality) therapy:

Radiation therapy:

Local control of pleural effusion (cornerstone of palliation):

Peritoneal mesothelioma:

Special Populations — Elderly and Renal/Hepatic Impairment

— Functional status (ECOG, Karnofsky) matters more than chronologic age for treatment decisions

— Comprehensive geriatric assessment recommended before aggressive therapy

— Polypharmacy review — many on anticoagulants, antiplatelets affecting surgical candidacy

— Higher risk of chemo toxicity: myelosuppression, nephrotoxicity, neuropathy

— Carboplatin AUC 5 preferred over cisplatin in elderly to reduce nephro/ototoxicity

— Single-agent pemetrexed an option for frail patients

— Immunotherapy generally well-tolerated in fit elderly — consider nivo/ipi

— Cisplatin contraindicated if CrCl <60 mL/min — substitute carboplatin dosed by Calvert formula

— Pemetrexed contraindicated if CrCl <45 mL/min — accumulates and causes severe toxicity

— Adjust dose; monitor renal function before each cycle

— Aggressive hydration with cisplatin, mannitol diuresis

— Avoid concurrent nephrotoxins (NSAIDs, aminoglycosides, IV contrast within 2 days of pemetrexed — NSAIDs can prolong pemetrexed half-life)

— Pemetrexed: limited data, generally tolerated with mild impairment

— Bevacizumab: caution with hepatic dysfunction

— Immunotherapy: baseline LFTs essential; immune-mediated hepatitis risk

— Bevacizumab risks: hypertension, arterial thrombosis, GI perforation, bleeding, proteinuria — relative contraindication with recent MI, uncontrolled HTN

— Pre-treatment echo, BP optimization

Step 3 management: Before starting cisplatin/pemetrexed in a 78-year-old, obtain CrCl, audiogram (if baseline hearing issues), CBC, CMP, B12/folate levels, and counsel to avoid NSAIDs around infusion. Substitute carboplatin if CrCl 45–60; hold pemetrexed if CrCl <45.

Board pearl: NSAID use within 2 days of pemetrexed in patients with renal impairment markedly increases toxicity — counsel patients to stop NSAIDs 2 days before through 2 days after each infusion.

Elderly patients (>75) comprise the majority of mesothelioma diagnoses due to long latency:

Renal impairment:

Hepatic impairment:

Cardiac comorbidity:

Special Populations — Pregnancy, Younger Patients, and BAP1 Carriers

— Multidisciplinary management (maternal-fetal medicine, oncology, surgery)

— Imaging: prefer MRI without gadolinium over CT when feasible

— Avoid chemotherapy in first trimester (teratogenicity); platinum-based chemo can be given in 2nd/3rd trimesters if needed

— Bevacizumab and immunotherapy generally avoided (limited safety data)

— Delivery timing balances maternal disease progression vs fetal maturity

— Consider BAP1 germline testing — autosomal dominant tumor predisposition (mesothelioma, uveal melanoma, RCC, cutaneous melanoma, basal cell carcinoma)

— Better prognosis than sporadic mesothelioma

— Family cascade testing if positive

— Genetic counseling referral

— Also consider radiation-induced mesothelioma in survivors of childhood Hodgkin or breast cancer (latency 15–30 years)

— Erionite exposure (specific geographic areas)

— Extremely rare; often associated with prior radiation or genetic syndromes

— Histology may differ (more sarcomatoid, peritoneal predominance)

— Navy veterans (1940s–1970s) have particularly high asbestos exposure rates

— Eligible for VA disability compensation — service-connected presumptive condition

— Refer to VA benefits counselor at diagnosis

— Cisplatin and alkylators are gonadotoxic; offer sperm/oocyte banking in reproductive-age patients before therapy

Board pearl: A patient <50 with mesothelioma, especially with personal/family history of uveal melanoma or renal cell carcinoma, should undergo BAP1 germline testing with genetic counseling — affects family screening and may influence treatment selection.

Step 3 management: Always ask new mesothelioma patients about military service — Navy veterans qualify for VA service-connected disability, and connecting them with a VSO (Veterans Service Officer) is part of comprehensive care.

Mesothelioma in pregnancy is exceedingly rare given typical age at diagnosis (60–80) but case reports exist:

Younger patients (<50):

Pediatric mesothelioma:

Veterans:

Fertility considerations:

Complications and Adverse Outcomes

— Recurrent malignant pleural effusion with dyspnea — most common

— Trapped lung — pleural rind prevents re-expansion after drainage; IPC required

— Chest wall invasion — severe somatic pain, often opioid-requiring

— Rib destruction, pathologic fractures

— Tract seeding — tumor nodules at thoracentesis/biopsy/chest tube sites

— SVC syndrome — facial swelling, plethora, neck vein distension; emergency

— Cardiac tamponade (pericardial mesothelioma) — Beck's triad, pulsus paradoxus

— Spinal cord compression from vertebral or paravertebral spread

— Recurrent laryngeal nerve palsy → hoarseness, aspiration risk

— Phrenic nerve palsy → diaphragmatic dysfunction

— Brachial plexopathy with apical disease

— Bowel obstruction, ascites in peritoneal disease

— Chemo: myelosuppression, febrile neutropenia, nephrotoxicity, neuropathy, mucositis

— Immunotherapy: irAEs — pneumonitis, colitis, hepatitis, thyroiditis, hypophysitis, adrenal insufficiency, myocarditis (rare but fatal)

— Bevacizumab: HTN, proteinuria, bleeding, thromboembolism, GI perforation, impaired wound healing

— Surgery: bronchopleural fistula, empyema, ARDS, atrial fibrillation, pulmonary embolism, persistent air leak

— Radiation: pneumonitis, esophagitis, cardiac toxicity

— Hypercoagulability with VTE

— Hypoglycemia

— Thrombocytosis (more a prognostic marker)

— DIC in advanced disease

Board pearl: Tract seeding at procedure sites is nearly pathognomonic for mesothelioma — appears as firm subcutaneous nodules at prior thoracentesis or chest tube sites within weeks to months. Treat with focal radiation or excision plus systemic therapy.

Step 3 management: For a mesothelioma patient on nivo/ipi presenting with new diarrhea (>6 stools/day) or dyspnea, hold immunotherapy, obtain CT, start high-dose corticosteroids (prednisone 1–2 mg/kg) for suspected immune-mediated colitis or pneumonitis — do not wait for biopsy confirmation.

Disease-related complications:

Treatment-related complications:

Paraneoplastic phenomena (uncommon):

When to Escalate — ICU, Consult, and Inpatient Triage

— Tension or massive symptomatic pleural effusion with respiratory distress → urgent thoracentesis or chest tube

— Cardiac tamponade → emergent pericardiocentesis

— SVC syndrome with airway compromise, cerebral edema → urgent stenting and/or RT

— Spinal cord compression → emergent MRI, IV dexamethasone (10 mg load, then 4 mg q6h), neurosurgery and radiation oncology consult, RT within 24 hours

— Febrile neutropenia (ANC <500, T ≥38.3°C) → blood cultures, broad-spectrum antibiotics (cefepime or pip-tazo) within 1 hour, MASCC risk stratification

— Severe immune-related adverse events (Grade 3–4 pneumonitis, colitis, hepatitis, myocarditis, hypophysitis with adrenal crisis) → hold ICI, high-dose steroids, sometimes infliximab/MMF

— Pulmonary embolism (mesothelioma is highly thrombogenic) → anticoagulation

— Pathologic fracture, severe uncontrolled pain → admit for pain control, palliative RT

— Bowel obstruction in peritoneal disease

— Thoracic oncology / medical oncology — diagnosis confirmation, systemic therapy

— Thoracic surgery — biopsy, pleurodesis, resection candidacy

— Radiation oncology — palliative and definitive RT planning

— Pulmonology — pleural procedures, IPC management

— Palliative care — early integration improves QoL and survival (Temel et al. paradigm applies)

— Pain management — chest wall pain often requires opioids ± neuropathic adjuvants (gabapentin, duloxetine)

— Genetic counseling — BAP1 testing in young/familial cases

— Social work / VSO — workers' comp, asbestos trust claims, VA benefits

CCS pearl: For cord compression in a known mesothelioma patient: immediate dexamethasone IV, urgent MRI whole spine, simultaneous consults to neurosurgery and radiation oncology, Foley catheter (urinary retention common), bed rest, DVT prophylaxis. Delay risks irreversible paralysis.

Step 3 management: Integrate palliative care at diagnosis, not at end-of-life — early palliative care in advanced thoracic malignancies improves both quality of life and overall survival.

Emergent indications for inpatient/ICU admission:

Specialty consults:

Key Differentials — Other Pleural Malignancies and Mimics

— Lung adenocarcinoma, breast, ovarian, GI primaries

— IHC distinguishes: TTF-1+, napsin A+, CEA+, MOC-31+, claudin-4+ (adeno) vs calretinin+, WT-1+, CK5/6+, D2-40+ (mesothelioma)

— Often presents with effusion + parenchymal lung mass (unlike mesothelioma which is pleura-predominant)

— May present with isolated effusion

— Flow cytometry on pleural fluid diagnostic

— Associated with HHV-8 (PEL), HIV

— Often a well-circumscribed pleural mass rather than diffuse rind

— CD34+, STAT6+ on IHC

— Most are benign; treated with resection

— Indolent variant, distinct from malignant mesothelioma

— Better prognosis

— Can mimic mesothelioma cytologically

— BAP1 loss and CDKN2A deletion distinguish malignant from reactive

Key distinction: Diffuse, circumferential, nodular pleural thickening involving the mediastinal pleura with associated effusion in an asbestos-exposed patient → mesothelioma until proven otherwise. Discrete pleural-based mass with parenchymal lung lesion → metastatic adenocarcinoma more likely.

Board pearl: Always pair two mesothelioma markers (calretinin + WT-1 or D2-40) with two carcinoma markers (TTF-1 + MOC-31 or claudin-4) in IHC workup — single-marker panels are insufficient and a common pitfall on exam stems featuring inadequate workup.

Metastatic adenocarcinoma to pleura — most common malignant pleural process overall:

Pleural lymphoma (primary effusion lymphoma, secondary lymphomatous involvement):

Pleural sarcoma / solitary fibrous tumor of pleura:

Pleural thymoma (rare ectopic implants).

Malignant pleural sarcomatoid lesions — overlap with sarcomatoid mesothelioma; IHC critical.

Mesothelioma in situ / well-differentiated papillary mesothelioma:

Reactive mesothelial hyperplasia:

Key Differentials — Benign and Infectious Mimics

— Fever, leukocytosis, productive cough, pleuritic chest pain

— Pleural fluid: low pH (<7.20), low glucose (<60), high LDH, neutrophil predominance

— Treat with antibiotics + chest tube drainage ± fibrinolytics ± VATS

— Distinguishable by acute course, infectious symptoms

— Subacute presentation, weight loss, low-grade fever, night sweats

— Pleural fluid: lymphocyte-predominant exudate, elevated adenosine deaminase (ADA >40 U/L), low glucose

— Pleural biopsy with granulomas + AFB or NAAT diagnostic

— Treat with RIPE × 6 months

— High-prevalence region or immigration history clue

— Develops within 10–20 years of exposure (earlier than mesothelioma)

— Small, exudative, often eosinophilic

— Diagnosis of exclusion — must follow patient ≥3 years to rule out evolving mesothelioma

— Resolves spontaneously; may leave pleural thickening

— Restrictive physiology, dyspnea

— Smooth thickening without nodularity

— Stable over time on imaging

— Asbestos-related; mimics tumor on CXR

— "Comet tail sign" on CT (vessels and bronchi curving into the lesion) — diagnostic

— Benign, no biopsy needed if classic features

Key distinction: BAPE develops 10–20 years after exposure; mesothelioma develops 20–50 years after. A small effusion appearing 15 years post-exposure that resolves is likely BAPE; one appearing 30 years later that persists or recurs is mesothelioma until proven otherwise.

Board pearl: The comet tail sign on CT distinguishes benign round atelectasis from a true pleural-based malignant mass — recognize it to avoid unnecessary biopsy.

Parapneumonic effusion / empyema:

Tuberculous pleurisy:

Benign asbestos pleural effusion (BAPE):

Pleural plaques: benign, asymptomatic, marker of exposure only.

Diffuse pleural thickening (non-malignant asbestos-related):

Round atelectasis (folded lung):

Rheumatoid pleuritis, lupus pleuritis — autoimmune, low glucose, RF+ in fluid.

Congestive heart failure — transudative bilateral effusions, distinguishable by Light's criteria and NT-proBNP.

Secondary Prevention, Discharge Planning, and Long-Term Care

— OSHA permissible exposure limit: 0.1 fiber/cc air, 8-hour TWA

— Asbestos abatement protocols for older buildings

— Personal protective equipment for at-risk workers

— Banned/restricted in many countries; still legal in limited US uses

— No effective screening test for mesothelioma — CT screening NOT recommended

— Smoking cessation reduces lung cancer (synergistic with asbestos) but does not reduce mesothelioma risk

— Annual symptom assessment in high-risk exposed cohorts

— Pneumococcal and influenza vaccinations

— Avoid further occupational exposure

— Clear written treatment plan and survivorship roadmap

— Medication reconciliation: chemo schedule, supportive meds (folic acid daily, B12 q9 weeks for pemetrexed; antiemetics; opioids and bowel regimen; PPI; DVT prophylaxis if applicable)

— Pain management plan (long-acting + breakthrough opioids; gabapentinoids for neuropathic component)

— Indwelling pleural catheter care: drainage schedule (every 1–3 days), home health nursing, infection signs

— Vaccinations: pneumococcal (PCV20 or PCV15→PPSV23), annual flu, COVID-19, RSV, herpes zoster, Tdap

— DVT/PE prophylaxis consideration in active cancer (mesothelioma is highly thrombogenic)

— Nutritional support: dietitian referral for weight loss, cachexia

— Pulmonary rehab for selected patients

— Advance care planning: POLST/MOLST, healthcare proxy, code status discussion early

Step 3 management: Within 1 week of discharge after mesothelioma diagnosis or treatment initiation, schedule: oncology, palliative care, primary care, social work (workers' comp/VA), and home health for IPC if placed. Use the CCS-style "schedule follow-up" approach systematically.

Board pearl: Low-dose CT screening for lung cancer (USPSTF) may benefit asbestos-exposed smokers for lung cancer detection, but does NOT prevent or screen for mesothelioma.

Primary prevention (population level):

Secondary prevention in exposed individuals:

For diagnosed patients — discharge and longitudinal care:

Follow-Up, Monitoring, and Rehabilitation

— CBC, CMP before every cycle

— Serum mesothelin (SMRP) — optional, can trend response in known epithelioid disease (not for diagnosis or screening)

— Imaging (CT chest with contrast) every 6–12 weeks during active therapy

— Response assessment by modified RECIST for mesothelioma (measures pleural rind thickness perpendicular to chest wall)

— Symptom assessment, performance status at each visit

— Pulmonary function testing if surgical candidate or post-RT

— TSH, free T4 every 6 weeks (thyroiditis common)

— Morning cortisol, ACTH if symptoms of adrenal insufficiency or hypophysitis

— LFTs, amylase/lipase, troponin (myocarditis), CK

— Pulse oximetry, low threshold for CT if new dyspnea/cough (pneumonitis)

— Skin, GI symptom inquiry at every visit

— CT chest every 3 months × 2 years, then every 6 months

— Clinic visit with oncology each interval

— Survivorship plan: late effects (cardiopulmonary, second malignancy, neuropathy)

— Pulmonary rehabilitation — improves dyspnea, exercise tolerance

— Physical therapy — counter deconditioning, cachexia

— Occupational therapy — energy conservation, ADL adaptation

— Psycho-oncology / counseling — high rates of depression, anxiety, existential distress

— Support groups (Mesothelioma Applied Research Foundation, ADAO)

— Caregiver support — high burden in this population

Step 3 management: For a mesothelioma patient on nivo/ipi reporting new exertional dyspnea at 6-week visit, order CT chest, pulse oximetry, TSH, cortisol, and consider holding ICI pending workup — pneumonitis vs disease progression vs hypothyroidism vs adrenal insufficiency must be distinguished before resuming therapy.

Board pearl: Mesothelioma response on CT uses modified RECIST, measuring pleural thickening perpendicular to the chest wall at multiple levels — standard RECIST poorly captures this disease.

On-treatment monitoring (during chemotherapy/immunotherapy):

Immunotherapy-specific monitoring:

Post-treatment surveillance:

Rehabilitation and supportive care:

Ethical, Legal, and Patient Safety Considerations

— Mesothelioma is a reportable occupational disease in most states

— Document exposure history meticulously — required for workers' compensation and asbestos bankruptcy trust fund claims

— Refer patients to a workers' compensation attorney or VSO (for veterans) — claims have statute of limitations (often 1–3 years from diagnosis)

— VA presumptive service connection for Navy veterans and other exposed service members

— Many patients/families recover significant compensation that funds care

— Multimodality therapy (surgery + chemo + RT) requires extensive risk discussion — EPP carries 5–7% perioperative mortality and major QoL impact

— Immunotherapy: discuss irreversible irAEs (type 1 diabetes, adrenal insufficiency) requiring lifelong hormone replacement

— Clinical trials: balance hope vs realistic expectations; ensure understanding of randomization

— Median survival often <18 months — early advance care planning is essential

— Document healthcare proxy, code status, preferences for hospice

— Address prognosis honestly — patients consistently report wanting prognostic information; withholding it harms autonomy

— Hospice referral when life expectancy <6 months and disease-directed therapy no longer beneficial

— Reconcile chemotherapy schedules, folic acid/B12, NSAID avoidance with pemetrexed

— Communicate IPC care across home health, PCP, oncology

— Prevent procedure-site tract seeding by minimizing unnecessary instrumentation

— Pain medication safety: opioid agreements, naloxone co-prescription, bowel regimens

— Household contacts may have had secondhand exposure — counsel on symptom awareness

— BAP1+ patients: cascade genetic testing and counseling for relatives

Step 3 management: At diagnosis, always provide written documentation of occupational exposure history and connect the patient to legal/compensation resources within 2 weeks — this is a concrete patient-safety and equity issue, as many families lose eligibility to statute-of-limitations delays.

Board pearl: Failure to refer for compensation/legal counsel is increasingly viewed as a quality-of-care lapse in mesothelioma management — analogous to failing to refer a lung cancer patient for smoking cessation.

Occupational disease reporting and compensation:

Informed consent edge cases:

Goals-of-care and end-of-life:

Patient safety in transitions of care:

Disclosure to family members:

High-Yield Associations and Rapid-Fire Facts

Board pearl: If a stem mentions "shipyard worker," "Navy veteran," "insulation installer," "brake mechanic," or "household exposure from a spouse," and unilateral pleural effusion with chest wall pain — the answer is mesothelioma. Order VATS biopsy, not repeat thoracentesis.

Step 3 management: Connect every patient to oncology, palliative care, legal counsel, and (if veteran) VA benefits at diagnosis.

Asbestos types: amphiboles (crocidolite "blue," amosite "brown," tremolite) > chrysotile "white" in mesothelioma risk

Latency: 20–50 years (median ~40)

No safe dose of asbestos

Smoking + asbestos: multiplicative for lung cancer, NOT for mesothelioma

Pleural plaques: marker of exposure, benign, do NOT become mesothelioma

BAP1 syndrome: mesothelioma + uveal melanoma + RCC + cutaneous melanoma — autosomal dominant

Erionite (zeolite): non-asbestos fiber causing mesothelioma in Cappadocia, Turkey; also in road gravel of Dunn County, North Dakota

SV40 virus: contaminated polio vaccines 1955–1963; controversial link

Radiation-induced mesothelioma: 15–30 year latency post Hodgkin lymphoma, breast cancer RT

Histology: epithelioid (best prognosis) > biphasic > sarcomatoid (worst)

IHC positive: calretinin, WT-1, CK5/6, D2-40, mesothelin

IHC negative: TTF-1, napsin A, CEA, MOC-31, claudin-4

BAP1 loss + CDKN2A deletion: distinguishes malignant from reactive

First-line chemo: cisplatin + pemetrexed (+ bevacizumab — MAPS trial)

First-line immunotherapy: nivolumab + ipilimumab (CheckMate 743) — preferred in non-epithelioid

Pemetrexed essentials: folic acid + B12 supplementation, avoid NSAIDs, renal dose adjust

Surgery: P/D preferred over EPP in modern practice (MARS trial)

Peritoneal mesothelioma: cytoreduction + HIPEC — best long-term survival

Pleural fluid: exudative, often bloody, low cytology yield (~30%)

VATS biopsy: gold standard for diagnosis

Tracheal deviation toward lesion: classic mesothelioma sign (vs away in simple effusion)

Tract seeding: nearly pathognomonic

Modified RECIST: standard response criteria

Median survival: 12–18 months with treatment; 6–9 without

Mesothelin (SMRP): monitoring marker, NOT screening

Board Question Stem Patterns

"68-year-old retired shipyard worker presents with 3 months of progressive dyspnea and right-sided chest wall pain. CXR shows large right pleural effusion. Thoracentesis yields bloody exudate; cytology is negative. CT shows nodular circumferential pleural thickening involving mediastinal pleura."

— Next step: VATS pleural biopsy (not repeat thoracentesis, not PET first)

"Pleural biopsy shows tumor cells positive for calretinin, WT-1, CK5/6 and negative for TTF-1, MOC-31, and napsin A."

— Diagnosis: epithelioid mesothelioma (not adenocarcinoma)

"Newly diagnosed unresectable epithelioid pleural mesothelioma in a 70-year-old with ECOG 1, CrCl 70."

— Answer: cisplatin + pemetrexed (+ bevacizumab if eligible)

— If sarcomatoid/biphasic: nivolumab + ipilimumab

"Patient on pemetrexed presents with severe pancytopenia and mucositis after first cycle."

— Likely cause: missed folic acid/B12 supplementation OR concurrent NSAID use OR renal impairment

"Recurrent symptomatic pleural effusion despite drainage, with non-expandable lung after thoracentesis."

— Best management: indwelling pleural catheter (IPC), NOT talc pleurodesis (which requires lung re-expansion)

"Mesothelioma patient with back pain, lower extremity weakness, urinary retention."

— Immediate: IV dexamethasone, urgent MRI whole spine, radiation oncology consult

"Patient 8 weeks into nivo/ipi develops fatigue, hypotension, hyponatremia."

— Workup: AM cortisol, ACTH; consider adrenal insufficiency from hypophysitis; treat with stress-dose hydrocortisone

"Patient asks about screening her husband (also a shipyard worker)."

— Answer: no effective screening; symptom awareness, smoking cessation, avoid further exposure

Board pearl: When a stem provides a complete classic exposure history + clinical picture, do NOT default to PET-CT or repeat thoracentesis — go straight to VATS biopsy for definitive tissue diagnosis.

Step 3 management: Recognize the immunotherapy irAE patterns — endocrine, GI, pulmonary, hepatic, cutaneous, cardiac — and the action is almost always: hold drug + high-dose steroids + specialty consult.

Classic stem 1 — diagnostic:

Stem 2 — IHC interpretation:

Stem 3 — first-line management:

Stem 4 — toxicity:

Stem 5 — palliation:

Stem 6 — emergency:

Stem 7 — irAE:

Stem 8 — counseling:

One-Line Recap

Malignant mesothelioma is an aggressive, asbestos-related neoplasm of mesothelial surfaces with a 20–50 year latency, diagnosed by VATS biopsy with IHC (calretinin/WT-1+, TTF-1−), managed by histology- and stage-tailored multimodality therapy (cisplatin/pemetrexed ± bevacizumab or nivolumab/ipilimumab; surgery in selected fit patients with epithelioid disease), with early palliative care, pleural drainage strategies, and immediate legal/compensation referral as integral parts of care.

Board pearl: The single most common Step 3 trap is treating mesothelioma as a purely oncologic problem — the correct comprehensive answer always includes occupational documentation, compensation referral, early palliative care, and survivorship planning alongside guideline-concordant systemic and local therapy.

Diagnosis: Asbestos-exposed patient + unilateral recurrent bloody exudative effusion + nodular pleural thickening involving mediastinal pleura → VATS biopsy with IHC panel including BAP1 and CDKN2A; cytology alone is inadequate.

First-line treatment: Cisplatin + pemetrexed ± bevacizumab for epithelioid; nivolumab + ipilimumab for sarcomatoid/biphasic; multimodality therapy (P/D + chemo ± RT) at a high-volume center for fit epithelioid stage I–II patients; HIPEC + cytoreduction for peritoneal disease.

Supportive care: Indwelling pleural catheter for recurrent effusion with trapped lung; talc pleurodesis if lung re-expands; early palliative care; aggressive pain control for chest wall invasion; vaccinations; VTE awareness; pulmonary rehabilitation.

Step 3-specific essentials: Document occupational history meticulously; refer to workers' compensation attorney, asbestos trust funds, and VA benefits (for veterans) within weeks of diagnosis; counsel household contacts on secondhand exposure; consider BAP1 germline testing in young or familial cases; supplement folic acid daily + B12 every 9 weeks with pemetrexed and avoid NSAIDs around infusion; integrate advance care planning early given a median survival of 12–18 months.